EDSA
Edesa Biotech IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$52.43M
P/E Ratio
—
EPS
$-1.07
Beta
-0.68
52W High
$9.37
52W Low
$0.72
50-Day MA
$4.04
200-Day MA
$2.55
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
0.18
PEG Ratio
—
About Edesa Biotech Inc
Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, is engaged in the research and development, manufacture and marketing of pharmaceuticals for inflammatory and immune-related diseases. The company is headquartered in Markham, Canada.
Fundamentals
| Revenue (TTM) | 500 |
| Gross Profit (TTM) | 311,200 |
| EBITDA | $-8.25M |
| Operating Margin | 0.00% |
| Return on Equity | -96.40% |
| Return on Assets | -55.30% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $0.56 |
| Price-to-Book | 10.53 |
| Price-to-Sales (TTM) | 130462.29 |
| EV/Revenue | 140491.25 |
| EV/EBITDA | -1.25 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -99.90% |
| Shares Outstanding | $8.89M |
| Float | $3.48M |
| % Insiders | 13.55% |
| % Institutions | 49.02% |
Analyst Ratings
Consensus ($11.00 target)
2
BuyData last updated: 4/14/2026